Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas

Metronomic chemotherapy (MCT) involves the chronic administration of doses of chemotherapy drugs that are below the maximum tolerated dose (MTD), at frequent and regular intervals, without extended rest periods [1]. It aims to achieve a balance between efficacy in tumor killing and lack of toxicity....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mainetti, Leandro Ernesto, Rico, María José, Fernández Zenobi, María Virginia, Perroud, Herman A., Roggero, Eduardo, Rozados, Viviana R., Scharovsky, O. Graciela
Formato:	article artículo publishedVersion
Lenguaje:	Inglés
Publicado:	Oxford University Press 2018
Materias:	Angiogenesis Cyclophosphamide doxorubicin toxicity
Acceso en línea:	http://hdl.handle.net/2133/11094 http://hdl.handle.net/2133/11094
Aporte de:	Repositorio Hipermedial de la Universidad Nacional de Rosario (UNR) de Universidad Nacional de Rosario

Ejemplares similares

Comparative Effectiveness of Two Metronomic Chemotherapy Schedules. Our Experience in the Preclinical Field
por: Rico, María José, et al.
Publicado: (2018)

Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response
por: Perroud, Herman A, et al.
Publicado: (2018)

The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamide
por: Rozados, Viviana R., et al.
Publicado: (2012)

Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
por: Perroud, Herman A, et al.
Publicado: (2018)

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
por: Perroud, Herman A, et al.
Publicado: (2018)

Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer
por: Perroud, Herman A, et al.
Publicado: (2018)

Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity
por: Rozados, Viviana R., et al.
Publicado: (2012)

Lovastatin enhances the antitumoral and apoptotic activity of doxorubicin in murine tumor models
por: Rozados, Viviana R., et al.
Publicado: (2012)

Metronomic chemotherapy: changing the paradigm that more is better
por: Scharovsky, O. Graciela, et al.
Publicado: (2012)

Co-treatment of tumor cells with hyaluronan plus doxorubicin affects endothelial cell behavior independently of VEGF expression
por: Vitale, Daiana Luján, et al.
Publicado: (2023)

A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma
por: Blajman, C., et al.

A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma
Publicado: (1999)

Inmunomodulación y antiangiogénesis en la terapéutica oncológica. De la investigación básica a la clínica
por: Scharovsky, O. Graciela, et al.
Publicado: (2012)

Regulatory T cells but not NKT I cells are modulated by a single low-dose cyclophosphamide in a B cell lymphoma tumor-model
por: Rico, María José, et al.
Publicado: (2012)

Binding and Encapsulation of Doxorubicin on Smart Pectin Hydrogels for Oral Delivery
por: Bosio, Valeria Elizabeth, et al.
Publicado: (2012)

The use of cyclophosphamide as an enhancer of the vaccine against foot-and-mouth disease
por: Portiansky, Enrique Leo, et al.
Publicado: (1996)

A Novel Synergistic Combination of Cyclophosphamide and Gene Transfer of Interleukin-12 Eradicates Colorectal Carcinoma in Mice
por: Malvicini, Mariana, et al.
Publicado: (2012)

The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide
por: Zacarías Fluck, M.F., et al.

Folic acid magnetic nanotheranostics for delivering doxorubicin: toxicological and biocompatibility studies on Zebrafish embryo and larvae
por: Igartúa, Daniela Edith, et al.
Publicado: (2018)

Genistein suppresses doxorubicin associated genotoxicity in human lymphocytes
por: Beg, Tanveer, et al.
Publicado: (2011)

Hyponatremia induced by high-dose cyclophosphamide therapy: a retrospective cohort study Cyclophosphamide and Hyponatremia.
por: Bonella, Belen Maria, et al.
Publicado: (2017)

The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide
por: Salatino, Mariana, et al.
Publicado: (2012)

Reversal of estrogen-resistance in murine mammary adenocarcinomas
por: Montecchia, M.F., et al.

Reversal of estrogen-resistance in murine mammary adenocarcinomas
Publicado: (1999)

Reversal of estrogen-resistance in murine mammary adenocarcinomas
por: Montecchia, M.F
Publicado: (1999)

Vacuum foam dried sugar-phosphate amorphous mixtures for stabilization of doxorubicin hydrochloride
por: Hajare, Ashok A., et al.
Publicado: (2010)

Self-assembly of carrageenin–CaCO3 hybrid microparticles on bacterial cellulose films for doxorubicin sustained delivery
por: Cacicedo, Maximiliano Luis, et al.
Publicado: (2015)

Modulation of IL-10/IL-10R expression by mafosfamide, a derivative of 4-hydroxycyclophosphamide, in a rat B-cell lymphoma
por: Rico, María José, et al.
Publicado: (2013)

A mammary adenocarcinoma murine model suitable for the study of cancer immunoediting
por: Pagura, Lucas, et al.
Publicado: (2018)

Protective and immunostimulating activity of a low dose of cyclophosphamide in the experimental infection of mice with foot-and-mouth disease virus
por: Portiansky, Enrique Leo, et al.
Publicado: (1989)

Influence of mast cells on two murine mammary adenocarcinomas
por: De Cidre, L.L., et al.

Influence of mast cells on two murine mammary adenocarcinomas
por: Eijan, Ana María, et al.
Publicado: (1996)

Influence of mast cells on two murine mammary adenocarcinomas
por: De Cidre, L.L
Publicado: (1996)

Modified bacterial cellulose scaffolds for localized doxorubicin release in human colorectal HT-29 cells
por: Cacicedo, Maximiliano Luis, et al.
Publicado: (2016)

Potentiation of the 5-aminolevulinic acid-based photodynamic therapy with cyclophosphamide
por: Casas, A., et al.

Potentiation of the 5-aminolevulinic acid-based photodynamic therapy with cyclophosphamide
por: Casas, Adriana Gabriela, et al.
Publicado: (1997)

Metabolic changes in the heme pathway driven by cyclophosphamide treatment in mice.
por: Casas, A., et al.

Metabolic changes in the heme pathway driven by cyclophosphamide treatment in mice.
por: Casas, Adriana Gabriela, et al.
Publicado: (1997)

Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24–25 June 2014, Milan
por: Bouche, Gauthier, et al.
Publicado: (2018)

Melatonin reverses oxidative damage in the submandibular gland of rats treated with Cyclophosphamide
por: Bachmeier, Evelin, et al.
Publicado: (2023)